SilcsBio

SilcsBio is a private, platform-focused biotechnology company that provides advanced computer-aided drug design (CADD) software and services. Its core technology, SILCS, combines rigorous physics-based molecular simulations with machine learning to predict ligand binding and dissociation kinetics, offering a significant edge in identifying and optimizing novel drug candidates. The company operates a hybrid business model, offering its software platform, targeted solution modules, and expert consulting services to drug discovery teams, positioning it as an enabler rather than a traditional therapeutic developer. Founded in 2012, SilcsBio has established academic and industry collaborations and continues to enhance its platform with AI-driven capabilities like koff prediction.

SILCS (Site Identification by Ligand Competitive Saturation) is a computational chemistry platform that uses molecular dynamics simulations with explicit solvent and protein flexibility to generate 3D free energy maps ('FragMaps'). These maps visualize the binding affinity of various functional groups across a protein's surface, revealing cryptic pockets and enabling drug design. The platform is augmented with AI/ML for predicting ligand dissociation kinetics (koff).

SilcsBio competes in the computer-aided drug design (CADD) software and services market against large public companies like Schrödinger and Dassault Systèmes (BIOVIA), as well as numerous private AI-driven drug discovery startups. Its differentiation lies in its rigorous physics-based FragMaps methodology combined with machine learning for kinetics, offering a unique approach to visualizing and quantifying the complete functional group affinity landscape of a protein.